Armodafinil and Rasagiline interaction
Armodafinil and Rasagiline: both prescribing labels describe an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Armodafinil (Nuvigil) label · effective 2025-09-02
Monoamine Oxidase (MAO) Inhibitors Caution should be used when concomitantly administering MAO inhibitors and NUVIGIL.
From the Rasagiline label · effective 2020-06-30
Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications.
Severe hypertension has been reported in patients taking the recommended dose of rasagiline and ophthalmic drops containing sympathomimetic medications.
Nevertheless, caution should be exercised when concomitantly using recommended doses of rasagiline with any sympathomimetic medications including nasal, oral, and ophthalmic decongestants and cold remedies.
Sympathomimetic Medications The concomitant use of rasagiline and sympathomimetic medications was not allowed in clinical studies.
Severe hypertensive reactions have followed the administration of sympathomimetics and nonselective MAO inhibitors.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.